November 5, 2024 02:34 PM EST

Cerebral to pay nearly $3.7M over controlled substance prescribing practices

Shelby Livingston

Senior health tech reporter

Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cerebral to pay nearly $3.7M over controlled substance prescribing practices

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Cere­bral to pay near­ly $3.7M over con­trolled sub­stance pre­scrib­ing prac­tices

Senior health tech reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Cerebral to pay nearly $3.7M over controlled substance prescribing practices